Research programme: small molecule therapeutics - Global Blood Therapeutics/Sanofi
Latest Information Update: 11 Oct 2022
At a glance
- Originator Sanofi
- Developer Global Blood Therapeutics; Sanofi
- Class Antianaemics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Sickle cell anaemia